ATE366806T1 - Dna-molekül, herstellung und verwendung in der gentherapie - Google Patents

Dna-molekül, herstellung und verwendung in der gentherapie

Info

Publication number
ATE366806T1
ATE366806T1 AT96904886T AT96904886T ATE366806T1 AT E366806 T1 ATE366806 T1 AT E366806T1 AT 96904886 T AT96904886 T AT 96904886T AT 96904886 T AT96904886 T AT 96904886T AT E366806 T1 ATE366806 T1 AT E366806T1
Authority
AT
Austria
Prior art keywords
production
gene therapy
dna molecule
genes
interest
Prior art date
Application number
AT96904886T
Other languages
English (en)
Inventor
Beatrice Cameron
Joel Crouzet
Anne-Marie Darquet
Daniel Scherman
Pierre Wils
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366806(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE366806T1 publication Critical patent/ATE366806T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AT96904886T 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie ATE366806T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502117A FR2731014B1 (fr) 1995-02-23 1995-02-23 Molecules d'adn, preparation et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ATE366806T1 true ATE366806T1 (de) 2007-08-15

Family

ID=9476445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904886T ATE366806T1 (de) 1995-02-23 1996-02-21 Dna-molekül, herstellung und verwendung in der gentherapie

Country Status (19)

Country Link
US (3) US6143530A (de)
EP (1) EP0815214B1 (de)
JP (1) JPH11500618A (de)
KR (1) KR19980702406A (de)
AT (1) ATE366806T1 (de)
AU (1) AU709111B2 (de)
BR (1) BR9607273A (de)
CA (1) CA2211427C (de)
CZ (1) CZ266897A3 (de)
DE (1) DE69637156T2 (de)
FI (1) FI973467L (de)
FR (1) FR2731014B1 (de)
HU (1) HUP9801216A3 (de)
IL (1) IL117214A0 (de)
MX (1) MX9706109A (de)
NO (1) NO973838L (de)
SK (1) SK114397A3 (de)
WO (1) WO1996026270A1 (de)
ZA (1) ZA961484B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
AU752704B2 (en) 1997-10-24 2002-09-26 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
CA2323831A1 (fr) * 1998-03-24 1999-09-30 Aventis Pharma S.A. Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
FR2776669B1 (fr) * 1998-03-24 2001-06-15 Rhone Poulenc Rorer Sa Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
WO2000011155A1 (en) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for genomic modification
EP1165813A2 (de) 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Lineare und zirkuläre expressionselemente
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
ATE303820T1 (de) * 1999-12-30 2005-09-15 Aventis Pharma Sa Verwendung von einem für einem anti-angiogenen faktor codierenden vektor zur behandlung von vaskularisation der hornhaut
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
KR100853040B1 (ko) * 2000-05-26 2008-08-19 센텔리옹 에스아에스 고정된 올리고뉴클레오타이드로 삼중나선 형성의 정제방법
WO2002008409A2 (en) * 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agriculture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
CN1498276A (zh) * 2001-03-23 2004-05-19 ��������I�����ɷ� 通过三螺旋相互作用纯化与检测双链dna靶序列的方法
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
AU2002247848A1 (en) * 2001-04-10 2002-10-28 Imperial College Innovations Limited Methods for the production of minicircles
GB0108968D0 (en) * 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
BR0209989A (pt) * 2001-05-30 2005-04-12 Chromos Molecular Systems Inc Plataformas baseadas em cromossomas
WO2003004088A2 (en) 2001-07-05 2003-01-16 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US20030108524A1 (en) * 2001-10-18 2003-06-12 Melissa Diagana Vectors for expressing multiple transgenes
EP1541674B9 (de) 2002-06-18 2011-09-14 Eisai R&D Management Co., Ltd. Primäre kultivierte adipozyten zur gentherapie
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
CA2498518A1 (en) 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US20040166512A1 (en) * 2002-11-12 2004-08-26 Kahn Michael L. Method for cloning PCR products without restriction or ligation enzymes
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
EP1631672B1 (de) * 2003-06-10 2006-09-20 Mologen AG Zirkuläres expressionskonstrukt für gentherapeutische anwendungen
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
WO2006078979A2 (en) * 2005-01-20 2006-07-27 Nature Technology Corp. Vectors and methods for genetic immunization
WO2006122354A1 (en) * 2005-05-17 2006-11-23 Ozgene Pty Ltd Sequential cloning system
AU2007211334A1 (en) * 2006-02-01 2007-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2009018500A1 (en) * 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
DK2304025T3 (en) 2008-07-03 2016-02-08 Univ Leland Stanford Junior MINI CIRCULAR DNA vector compositions and methods for their preparation and use
WO2011057825A1 (en) 2009-11-16 2011-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction of gene expression in arthropods
DE102009054265A1 (de) 2009-11-16 2011-05-26 Giese, Matthias, Dr. Orale Verabreichung von DNA an Insekten
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
DE3876327D1 (de) * 1987-07-21 1993-01-14 Du Pont Merck Pharma Verfahren fuer die herstellung von in tierischen zellen stabilen und lebensfaehigen rekombinanten viralen vektoren.
FR2631634B1 (fr) * 1988-05-18 1991-06-14 Centre Nat Rech Scient Vecteurs de clonage et d'expression dans une souche d'actinomycete, procede de transformation de cette souche, souche d'actynomycete obtenue et preparation de proteines
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
EP0656941B1 (de) * 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US5401632A (en) * 1992-07-16 1995-03-28 Wisconsin Alumni Research Foundation Triple helix purification and sequencing
AU5405994A (en) * 1992-10-16 1994-05-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Supercoiled minicircle dna as as a unitary promoter vector
WO1995020652A1 (de) * 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy

Also Published As

Publication number Publication date
AU4882296A (en) 1996-09-11
CZ266897A3 (en) 1997-11-12
EP0815214B1 (de) 2007-07-11
SK114397A3 (en) 1998-02-04
US20030104444A1 (en) 2003-06-05
DE69637156D1 (de) 2007-08-23
FI973467A0 (fi) 1997-08-22
ZA961484B (en) 1996-08-28
AU709111B2 (en) 1999-08-19
EP0815214A1 (de) 1998-01-07
KR19980702406A (ko) 1998-07-15
FI973467A7 (fi) 1997-08-22
NO973838D0 (no) 1997-08-20
FR2731014A1 (fr) 1996-08-30
US6143530A (en) 2000-11-07
NO973838L (no) 1997-10-13
DE69637156T2 (de) 2008-02-07
BR9607273A (pt) 1998-07-21
WO1996026270A1 (fr) 1996-08-29
CA2211427A1 (fr) 1996-08-29
IL117214A0 (en) 1996-06-18
HUP9801216A2 (hu) 1998-08-28
HUP9801216A3 (en) 2001-08-28
FI973467L (fi) 1997-08-22
US6492164B1 (en) 2002-12-10
MX9706109A (es) 1997-11-29
FR2731014B1 (fr) 1997-03-28
JPH11500618A (ja) 1999-01-19
CA2211427C (fr) 2010-12-14

Similar Documents

Publication Publication Date Title
ATE366806T1 (de) Dna-molekül, herstellung und verwendung in der gentherapie
DE69638183D1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
WO2001002568A3 (en) Human genes and gene expression products
ATE167680T1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
ATE163046T1 (de) Genetische veränderung von endothelzellen
NO973685L (no) Multi-tumor avvikende vekstgener
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
ATE319854T1 (de) Enzymaktive dna moleküle
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
DE69736840D1 (de) Synthese von nukleosiden und polynukleotiden
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
ATE204481T1 (de) Medizinische zusammensetzung zur verwendung für die transfektion und in vivoexpression von exogenen
DE69532485D1 (de) Trehalose-freisetzendes Enzym, dafür kodierende DNA, Herstellung und Verwendung
FI925359A0 (fi) Kloning och expression av dna-molekyler, som kodar foer arabinandegraderande enzymer av svampursprung
DK0877758T3 (da) Oprenset SR-p70-protein
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
DE69329164D1 (de) Protein mit Alpha-Glukosidase-Aktivität, DNS mit dessen genetischer Information und Herstellung von Alpha-Glukosidase
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
DE69828654D1 (de) Isolierung und Verwendung von Nukleinsäuremolekülen, welche für Mitglieder der SSX-Familie kodieren
EP1124840A4 (de) Ovarspezifische gene und proteine
WO2001098350A3 (en) Compositions comprising net-4 modulations and their use for treating neoplastic disease
MX9709596A (es) Adn catal ??tico.
ATE311205T1 (de) Verwendung von viralen vektoren und geladenen molekülen für die gentherapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties